NEUMORA THERAPEUTICS, INC. Other Receivables, Net, Current
NEUMORA THERAPEUTICS, INC. (NMRA) had Other Receivables, Net, Current of $1.63 million as of 2024-06-30, per its 10-Q filed 2024-08-06.
Discontinued › Notes
us-gaap:OtherReceivablesNetCurrent · last filed 2024-08-06
- 2024-06-30: Other Receivables, Net, Current $1.63M.
- 2024-03-31: Other Receivables, Net, Current $906.00K.
- 2023-12-31: Other Receivables, Net, Current $939.00K.
- 2023-09-30: Other Receivables, Net, Current $668.00K.
| Period end | Other Receivables, Net, Current |
|---|---|
| 2024-06-30 | $1.63M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $906.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $939.00K 10-Q · filed 2024-08-06 |
| 2023-09-30 | $668.00K 10-Q · filed 2023-11-01 |
| 2022-12-31 | $919.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |